Horus Pharma Joins Formycon's Eylea® Biosimilar Commercialization

Formycon AG has announced that Horus Pharma will become an additional commercialization partner for the Eylea® biosimilar FYB203 in selected European countries, marketed under the brand name Baiama®. This agreement is part of a semi-exclusive partnership with Klinge Biopharma, which previously secured a similar deal with Teva Pharmaceuticals.

With this new collaboration, Klinge Biopharma will receive upfront and milestone payments, along with royalties from net sales. Formycon will benefit from these agreements, receiving additional service payments and organizing the supply chain for FYB203.

Aflibercept, the active compound in FYB203, treats neovascular age-related macular degeneration, amongst other retinal diseases. Horus Pharma, a leader in preservative-free ophthalmology products, aims to enhance coverage in Europe alongside Teva’s marketing efforts.